Melanoma Case Control Protocol Summary The study will assemble and follow up a population based cohort of a total of upto 2000 cutaneous melanoma patients.

Slides:



Advertisements
Similar presentations
WHAT ABOUT THE IMP? IMP HANDLING FOR THE TRIAL SITE PHARMACY.
Advertisements

AVAST-M Protocol Title A randomised trial evaluating the VEGF inhibitor, Bevacizumab (Avastin®),as adjuvant therapy following resection of AJCC stage IIB.
TPA… SMART or not SMART? That is the Question. Sarah Parker, MD.
1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.
Prophylaxis of Venous Thromboembolism
Modified Megestrol The Clinical Trials by : Carolina R. Akib
The short term effects of an AKT inhibitor (AZD5363) on biomarkers of the AKT pathway and anti-tumour activity in a breast cancer paired biopsy study (STAKT.
Sentinel Lymph Node Biopsy in Melanoma
Cases on 1st line use of Ipilimumab in BRAF+ patients, sequencing of therapies Erika Richtig.
Guidance on Cancer Services Improving Outcomes for People with Skin Tumours including Melanoma NICE Stateholder Consultation version July 2005.
Post Menopausal Bleeding
Skin Cancer Carlos Garcia MD Dermatology at OUHSC No conflicts of interest to disclose.
SYSTEMIC THERAPY FOR UNRESECTABLE STAGE III OR METASTATIC CUTANEOUS MELANOMA Sarkheil Mehdi Hematologist- oncologist.
Melanoma Hai Ho, M.D. Department of Family Practice.
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects.
Vulvar Cancer A. Gari MD..
Primary Aim To compare outcomes of participants with symptoms of stable angina or angina equivalent evaluated with an anatomic imaging strategy using CCTA.
Vascular issues associated with bevacizumab Stuart M. Lichtman, MD, FACP 65+ Clinical Geriatric Program Associate Attending Memorial Sloan-Kettering Cancer.
AGO-OVAR DESKTOP III (Protocol AGO - OVAR OP.4)
Cutaneous Malignancies
Resection For Lung Metastases M62 Coloproctology Course.
In the name of God Isfahan medical school Shahnaz Aram MD.
Stroke and the ED Kurian Thomas, MD Department of Neurology.
COLON CANCER A MAJOR ISSUE IN ALASKA. A common malignancy 200,000 cases in the U. S. in ,000 cases in the U. S. in 2008 Greater than 50 new cases.
ACRIN 6685 Overview ACRIN 6685 A Multi-center Trial of FDG-PET/CT Staging of Head and Neck Cancer and its Impact on the N0 Neck Surgical Treatment in Head.
Inclusion Criteria Patient has definitive histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas. The definitive diagnosis.
Skin Cancer Network Group Audit of Clinical Performance Indicators: Data quality and treatment quality Anna Murray BSc Cancer Information Analyst
Patterns of Care in Medical Oncology Adjuvant Systemic Therapy for Colon Cancer.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Best first ? The ATAC completed treatment analysis Professor Jack Cuzick Wolfson Institute of Preventive Medicine, London, UK.
Anal Cancer - Case 1  62 years old woman with 6 months history of anal pain  Clinically T 3 squamous cell carcinoma growing anteriorly  Which staging.
Safety of Cyclooxygenase-2 (COX-2) inhibitors, Valdecoxib and Parecoxib, versus Placebo for Post CABG Pain Management Presented at American College of.
THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.
MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.
Baseline characteristics. Patient flow Completed Completed Perindopril Placebo Randomised Not randomised Registered.
Copenhagen University Hospital Rigshospitalet, Denmark
Therapeutic Delay and Survival after Surgery for Cancer of the Pancreatic Head with or without Preoperative Biliary Drainage Eshuis, van der Gaag, Rauws.
Definition Signs & symptoms Treatment Root of the disease.
MITO 25 A randomized phase II trial of Carboplatin-Paclitaxel- Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab- Rucaparib vs Carboplatin-Paclitaxel-Rucaparib.
R3 정상완. Introduction  EGC : Tumor invasion is limited to the mucosa or submucosa, regardless of lymph node involvement.  Accumulated histopathological.
HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
MALIGNANT MELANOMA. Outline Introduction Aetiology Types Invasion and Metastasis Risk Factors Diagnosis and Staging Treatment and Prevention.
MELANOMA Stephen G. Mallette, D.O. Athens, Alabama.
RANDOMIZED PHASE II STUDY OF NABPACLITAXEL, IN RECURRENT ADVANCED OR METASTATIC CERVICAL CANCER MITO CER-NAB Enrica Mazzoni, MD Medical Oncology & Breast.
ELIGIBILITY CRITERIA- Summarised
MITO 25 A randomized phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib.
Brain imaging prior to lung cancer resection
MITO 27 Randomized Phase II study on Pembrolizumab plus chemotherapy versus chemotherapy alone in recurrent, platinum-resistant ovarian cancer (a MITO.
Università di Napoli Federico II
Melanoma Staging an update
MALIGNANT MELANOMA.
Post Menopausal Bleeding
Fondazione IRCCS Istituto Nazionale Tumori
Copenhagen University Hospital Rigshospitalet, Denmark
Broadening Eligibility Criteria to Make Clinical Trials More Representative Joint Recommendations of the American Society of Clinical Oncology and Friends.
Surgical Cancer Treatment
But how to treat those with positive SLNB? Results and Discussion
Jeff Macemon Waikato Cardiothoracic Unit
Dabigatran in myocardial injury after noncardiac surgery
‘Improving Outcomes for people with skin tumours, including Melanoma’
The STAR-TREC Trial SIV Presentation
pulmonary embolism protocol -- EMB review
Adjuvant Therapy in Melanoma
MITO 26 PHASE II TRIAL ON TRABECTEDIN IN THE TREATMENT OF ADVANCED UTERINE AND OVARIAN CARCINOSARCOMA (CS)
MITO 27 Randomized Phase II study on Pembrolizumab plus chemotherapy versus chemotherapy alone in recurrent, platinum-resistant ovarian cancer (a MITO.
Presentation transcript:

Melanoma Case Control Protocol Summary The study will assemble and follow up a population based cohort of a total of upto 2000 cutaneous melanoma patients aged from 18 to 75 years. They will be newly diagnosed patients with primary tumours in the period 2000 till A subset of patients with rare variants of melanoma of any breslow thickness (such as acral lentiginous, sub-ungual, ENT, oropharyngeal, perineal, vaginal, vulval, rectal and nodal disease with no known primary) will also be recruited. Eligibility Criteria 1.Melanoma cases with breslow thickness ≥ 0.75mm will be ascertained from various centres. The cases will be aged between 18 and 75 years and will have had an invasive melanoma. That is, that patients with in situ lesions/MIN lesions and lesions with breslow thickness <0.75mm will be excluded. Patients with lentigo maligna melanoma will be included. Patients throughout the uk with rare melanomas or undergoing sentinel node biopsy are also eligible subject to local R&D approval. Contact with these patients will only be made via their clinician. Occasionally there may be patients who refer themselves, for example having seen the study on the NCRN website, in which case a reply will be made to them directly. 2.The subset of rare melanomas will be recruited from various regions in the UK in the same manner as 1a, except there will be no upper age limit, or a limit on the date of recruitment post diagnosis, due to the small number of eligible patients. To give significant numbers, the intention will be to recruit these cases nationally and beyond 2008 to 2010, dependent upon funding. For all melanoma trials mentioned, contact details are: Alison Hassall: Ex4939Fran Lawton:

AVAST-M Exclusion Criteria 1.Non-cutaneous melanoma as the primary disease site. 2.Any evidence of distant or non-regional lymph node metastases. 3.Evidence of CNS metastases, even if previously treated. 4.Incomplete surgical resection of the disease. 5.Adjuvant radiotherapy ongoing at randomisation. 6.Prior chemotherapy, immunotherapy, or hormonal therapy within 12 weeks of randomisation 7.Any surgery (including open biopsy, but excluding insertion of an indwelling catheter), or significant traumatic injury within 28 days prior to randomisation, or 8.anticipation of the need for surgery during study treatment. 9.Current or recent (within 7 days of randomisation) use of aspirin (> 300 mg/day). 10.Current or recent (within 7 days of randomisation) use of full-dose oral or parenteral anticoagulants or thrombolytic agent for therapeutic purposes. 11.Prophylactic use of anticoagulants is allowed. 12.History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding. 13.Uncontrolled hypertension (blood pressures: systolic >150mmHg and/or diastolic >100mmHg). 14.Clinically significant (i.e. active) cardiovascular disease for example CVA (≤6 months before randomisation), myocardial infarction (≤6 months before randomisation), unstable angina, congestive heart failure NYHA Class ≥II, serious cardiac arrhythmia requiring medication during the study and might interfere with regularity of the study treatment, or not controlled by medication. 15.Non-healing wound, active peptic ulcer or bone fracture. 16.History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of randomisation. 17.Pregnant or breast-feeding females. 18.Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to randomisation. 19.Known hypersensitivity to bevacizumab or any of its excipients. 20.Evidence of any other disease, neurological or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications. 21. Any condition, which, in the opinion of the investigator, might interfere with the safety of the patient or evaluation of the study objectives. 22.Previous malignancy in the last 5 years except completely excised basal cell cancer of the skin or completely excised squamous cell cancer of the skin (Patients with completely excised in situ malignancies are eligible).